Parameter
| Biomarker | SLC1A5 | Full name | Solute carrier family 1 member 5 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Monitoring |
| Disease | PCOS | Disease Subtypes | / | ||
| Organ | Ovary | Test Sample / Technology Platform | PBMC/Ovarian Tissue (Real-time Fluorescence Quantitative PCR qRT-PCR, Immunohistochemistry IHC, WB) | ||
| Pathobiological Mechanisms | It is responsible for transporting glutamine into the cells. In patients with PCOS, the expression of SLC1A5 in ovarian granulosa cells and adipocytes is upregulated. By promoting glutamine metabolism reprogramming, it supports the synthesis of androgens in the ovaries and the inflammatory response of adipocytes, thereby aggravating insulin resistance. | ||||
| Clinical Availability Status | Frontier research stage: Metabolic target markers, actively exploring their clinical application value. | ||||
| Notes and Dynamics | The expression level of SLC1A5 is positively correlated with the fasting blood glucose, HOMA-IR and testosterone levels of patients with PCOS. Small molecule drugs that inhibit the function of SLC1A5 can reduce androgen levels and improve ovulation function in animal models, and are expected to become a new therapeutic target for PCOS. | ||||